Across TCGA pan-cancer cohorts, UBE2F mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated UBE2F data layer compared with 20 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher UBE2F mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated UBE2F expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where UBE2F mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	III,IV	0.369	0.894	.001	13	view →
LUAD	OS	Tertile	III,IV	0.329	0.723	.009	11	view →
PDAC	OS	Median	II,III,IV	0.707	0.955	.004	11	view →
HNSC	DFS	Median	IV	0.645	0.928	.004	3	view →
LSCC	DFS	Quartile	All	1.000	0.848	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: UBE2F tumor-vs-normal RNA expression · all UBE2F data types